Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception : findings from a randomised, multicentre, open-label trial

dc.contributor.authorBeksinska, Mags
dc.contributor.authorIssema, Rodal
dc.contributor.authorBeesham, Ivana
dc.contributor.authorLalbahadur, Tharnija
dc.contributor.authorThomas, Katherine
dc.contributor.authorMorrison, Charles
dc.contributor.authorHofmeyr, George Justus
dc.contributor.authorSteyn, Petrus S.
dc.contributor.authorMugo, Nelly
dc.contributor.authorPalanee-Phillips, Thesla
dc.contributor.authorAhmed, Khatija
dc.contributor.authorNair, Gonasagrie
dc.contributor.authorBaeten, Jared M.
dc.contributor.authorSmit, Jenni
dc.date.accessioned2022-02-16T10:26:29Z
dc.date.available2022-02-16T10:26:29Z
dc.date.issued2021-04
dc.description.abstractBACKGROUND : There is limited evidence on the impact of the use of progestin-only hormonal contraception (POC) on weight change. We conducted a secondary analysis of prospective weight change among women enrolled in the Evidence for Contraceptive options and HIV Outcomes (ECHO) trial. METHODS : The ECHO trial was conducted at 12 sites in eSwatini, Kenya, South Africa and Zambia between December 2015 and October 2018. HIV negative, women aged 16 35 years, desiring contraception, were randomised (1:1:1) to either 3-monthly intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel (LNG) implant or copper intrauterine device (IUD). Follow-up was up to 18 months. Weight (kg) was measured at baseline and study exit. Analysis was performed as intention to treat (ITT) and time on continuous contraceptive use. The primary outcome of this secondary analysis is weight change from study enrolment to the final visit at study month 12 18. The ECHO trial is registered with ClinicalTrials.gov, NCT02550067. FINDINGS : 7829 women were randomly assigned to DMPA-IM (n = 2609), copper IUD (n = 2607) or LNG implant (n = 2613). The ITT population included 7014 women 2293 DMPA-IM group, 2372 copper IUD group and 2349 LNG group) who were not lost to follow-up, pregnant on study, or missing weight data. The mean weight increased in all groups but was significantly different in magnitude: 3.5 kg (SD = 6.3), 2.4 kg (SD = 5.9) and 1.5 kg (SD = 5.7) in the DMPA-IM, LNG implant and copper IUD groups, respectively. Comparative differences between groups were (2.02 kg (95% CI, 1.68, 2.36, p < 0.001) for DMPA-IM versus copper IUD, 0.87 kg (0.53,1.20 p < 0.001) for LNG implant compared to copper IUD and 1.16 kg (0.82, 1.50, p < 0.001) for DMPAIM compared with LNG implant. Results for continuous contraceptive use were similar. INTERPRETATION : We found differences in weight gain between POC users compared to the non-hormonal copper IUD group over 12 18 months of use. Women using POCs should be counselled about this potential side effect when choosing a contraceptive method.en_ZA
dc.description.departmentMedical Microbiologyen_ZA
dc.description.librarianam2022en_ZA
dc.description.sponsorshipBill & Melinda Gates Foundation, US Agency for International Development (USAID) and the President’s Emergency Plan for AIDS Relief, Swedish International Development Cooperation Agency, South African Medical Research Council, and UNFPA.en_ZA
dc.description.urihttp://www.journals.elsevier.com/eclinicalmedicineen_ZA
dc.identifier.citationBeksinska, M., Issema, R., Beesham, I. et al. 2021, 'Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, ulticentre, open-label trial', EClinicalMedicine, vol. 34, art. 100800, pp. 1-9.en_ZA
dc.identifier.issn2589-5370 (online)
dc.identifier.other10.1016/j.eclinm.2021.100800
dc.identifier.urihttp://hdl.handle.net/2263/83983
dc.language.isoenen_ZA
dc.publisherElsevieren_ZA
dc.rights© 2021 The Author(s). This is an open access article under the CC BY license.en_ZA
dc.subjectDepot medroxyprogesterone acetateen_ZA
dc.subjectCopper intrauterine deviceen_ZA
dc.subjectLevonorgestrel implanten_ZA
dc.subjectContraceptionen_ZA
dc.subjectWeighten_ZA
dc.subjectBody mass index (BMI)en_ZA
dc.subjectIntrauterine device (IUD)en_ZA
dc.subjectEvidence for contraceptive options and HIV outcomes (ECHO)en_ZA
dc.subjectProgestin-only hormonal contraception (POC)en_ZA
dc.subjectIntramuscular depot medroxyprogesterone acetate (DMPA-IM)en_ZA
dc.subjectLevonorgestrel (LNG)en_ZA
dc.titleWeight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception : findings from a randomised, multicentre, open-label trialen_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Beksinska_Weight_2021.pdf
Size:
839.66 KB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Beksinska_WeightTabS1_2021.pdf
Size:
74.58 KB
Format:
Adobe Portable Document Format
Description:
Table S1

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: